Utilization of microarrayed compound screening (microARCS) to identify inhibitors of p56lck tyrosine kinase.
Protein tyrosine kinases play critical roles in cell signaling and are considered attractive targets for drug discovery. The authors have applied microARCS (microarrayed compound screening) technology to develop a high-throughput screen for finding inhibitors of the p56lck tyrosine kinase. Initial assay development was performed in a homogeneous time-resolved (LANCE) format in 96-well microplates and then converted into the gel-based microARCS format. The microARCS methodology is a well-less screening format in which 8640 compounds are arrayed on a microplate-sized piece of polystyene and subsequently assayed by placing reagents cast in agarose gels in contact with these compound sheets. A blotting paper soaked with adenosine triphosphate is applied on the gel to initiate the kinase reaction in the gel. Using this screening methodology, 300,000 compounds were screened in less than 40 h. Substantial reagent reduction was achieved by converting this tyrosine kinase assay from a 96-well plate assay to microARCS, resulting in significant cost savings.
Abbott Laboratories, Global Pharmaceutical Research Development, Abbott Park, IL 60064-6181, USA.
Gail
G
Freiberg
Julie
J
Wilkins
Caroline
C
David
James
J
Kofron
Yong
Y
Jia
Gavin C
GC
Hirst
David J
DJ
Burns
Usha
U
Warrior
D004587:Electrophoresis, Agar Gel; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D019860:Lymphocyte Specific Protein Tyrosine Kinase p56(lck) / Q000037:antagonists & inhibitors*; D020411:Oligonucleotide Array Sequence Analysis; D013379:Substrate Specificity
D004791:Enzyme Inhibitors; D019860:Lymphocyte Specific Protein Tyrosine Kinase p56(lck)